...VITA also will acquire raw material and equipment related to the production of the company's Vitagel...
...procedures as an adjunct to hemostasis. AGN will receive $6.6 million. VITA has rights to Vitagel...

...$9 million to eliminate the royalties it owes under a 204 deal to market ANP's Vitagel...
...2017, and eliminates certain termination rights and eliminates VITA's obligation to meet minimal sales requirements. Vitagel...

...Vitagel surgical hemostat. The new approval permits Orthovita to sell Vitagel. Orthovita has been distributing Vitagel...
...ineffective. Angiotech Pharmaceuticals Inc. (TSX:ANP; ANPI), Vancouver, B.C. Orthovita Inc. (VITA; EASD:VITA), Malvern, Penn. Product: Vitagel...

...VITA received North American rights to sell and distribute ANP's Costasis surgical hemostat for use in...
...hemostat for use in spine and orthopedic surgery. The companies plan to rename the compound Vitagel...

...its device-coating technology with CSON's biomaterials, which include the marketed products CoSeal surgical sealant and CoStasis...

...therapeutics, such as paclitaxel-coated stents, with CSON's biomaterials. CSON markets its CoSeal surgical sealant and CoStasis...

...therapeutics, such as paclitaxel-coated stents, with CSON's biomaterials. CSON markets its CoSeal surgical sealant and CoStasis...

...The FDA approved an expanded label for CoStasis to include stopping or controlling active bleeding during...
...procedures except neurological, ophthalmic and urological surgeries. Cohesion Technologies Inc. (CSON), Palo Alto, Calif. Product: CoStasis...

...resulting in expected annual savings of $1.5 million, and will focus its resources on its CoStasis...

...The FDA granted marketing clearance for CSON's CoStasis surgical hemostat used to stop or control active...
...marketing partner U.S. Surgical Corp. (Norwalk, Conn.). Cohesion Technologies Inc. (CSON), Palo Alto, Calif. Product: CoStasis...